SE0300959D0 - Methods for predicting therapeutic response to agents acting on the growth hormone receptor - Google Patents

Methods for predicting therapeutic response to agents acting on the growth hormone receptor

Info

Publication number
SE0300959D0
SE0300959D0 SE0300959A SE0300959A SE0300959D0 SE 0300959 D0 SE0300959 D0 SE 0300959D0 SE 0300959 A SE0300959 A SE 0300959A SE 0300959 A SE0300959 A SE 0300959A SE 0300959 D0 SE0300959 D0 SE 0300959D0
Authority
SE
Sweden
Prior art keywords
methods
growth hormone
hormone receptor
therapeutic response
agents acting
Prior art date
Application number
SE0300959A
Other languages
English (en)
Swedish (sv)
Inventor
Pierre Bougneres
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of SE0300959D0 publication Critical patent/SE0300959D0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
SE0300959A 2002-12-19 2003-04-02 Methods for predicting therapeutic response to agents acting on the growth hormone receptor SE0300959D0 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43486102P 2002-12-19 2002-12-19

Publications (1)

Publication Number Publication Date
SE0300959D0 true SE0300959D0 (sv) 2003-04-02

Family

ID=23725994

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300959A SE0300959D0 (sv) 2002-12-19 2003-04-02 Methods for predicting therapeutic response to agents acting on the growth hormone receptor

Country Status (12)

Country Link
US (1) US20040180358A1 (hr)
EP (1) EP1572738A1 (hr)
JP (1) JP2006525785A (hr)
KR (1) KR20050085855A (hr)
CN (1) CN1747968A (hr)
AU (1) AU2003278503A1 (hr)
CA (1) CA2510045A1 (hr)
HR (1) HRP20050563A2 (hr)
NO (1) NO20053490L (hr)
RU (1) RU2005122665A (hr)
SE (1) SE0300959D0 (hr)
WO (1) WO2004056864A1 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070029245A (ko) * 2004-07-08 2007-03-13 파마시아 앤드 업존 캄파니 엘엘씨 성장 호르몬 수용체에 작용하는 약제에 대한 치료 반응의예측 방법
GB0600122D0 (en) * 2006-01-05 2006-02-15 Univ Cardiff Mutation in the growth hormone receptor
WO2008109357A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
ES2643641T3 (es) * 2009-06-08 2017-11-23 Amunix Operating Inc. Polipéptidos de hormona del crecimiento y métodos de producción y uso de los mismos
CN107385034B (zh) * 2009-09-03 2021-08-17 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
EP2846822A2 (en) * 2012-05-11 2015-03-18 Prorec Bio AB Method for diagnosis and treatment of prolactin associated disorders
CN103014005A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼a-fabp蛋白基因、重组蛋白及其克隆方法
CN103014007A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼α-乳白蛋白基因、重组蛋白及其克隆方法
CN103014008A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼ghr蛋白基因、重组蛋白及其克隆方法
CN112322657B (zh) * 2020-11-12 2023-04-25 浙江新码生物医药有限公司 一种人生长激素的体外活性检测方法
IL309196A (en) 2021-06-18 2024-02-01 Peptidream Inc GHR-binding peptide and composition containing it

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
CA2197408A1 (en) * 1996-02-13 1997-08-14 Kazuo Chihara Mutant human growth hormones and their uses
US6080911A (en) * 1997-04-15 2000-06-27 Ohio University Mice models of growth hormone insensitivity

Also Published As

Publication number Publication date
AU2003278503A1 (en) 2004-07-14
CA2510045A1 (en) 2004-07-08
EP1572738A1 (en) 2005-09-14
RU2005122665A (ru) 2006-01-20
JP2006525785A (ja) 2006-11-16
KR20050085855A (ko) 2005-08-29
CN1747968A (zh) 2006-03-15
NO20053490D0 (no) 2005-07-18
HRP20050563A2 (en) 2005-12-31
NO20053490L (no) 2005-09-16
WO2004056864A1 (en) 2004-07-08
US20040180358A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
NO20053490L (no) Methods for prediciting therapeutic response to agents acting on the growth hormone receptor
BR0316969A (pt) Tratamento de mal de huntington com epa
IN2015KN00290A (hr)
ATE552849T1 (de) Behandlungsverfahren unter verwendung von ctla-4 antikörpern
WO2004000094A8 (en) Predictive markers in cancer therapy
WO2000050639A3 (en) Gene sequence variations with utility in determining the treatment of disease
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2003057856A3 (en) Dominant negative proteins and methods thereof
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2002098355A3 (en) Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2004081043A3 (en) Baff mutants with at least one amino acid substitution and methods of their production
AU2001245319A1 (en) Methods of treating diseases with activated protein c
NO993653L (no) FremgangsmÕte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
AU1955899A (en) Mammalian edg-7 receptor homologs
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO2005002414A3 (en) Prognosis determination in ewing sarcoma patients by means of genetic profiling
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
TW200617396A (en) Method
WO2004048548A3 (en) Methods for identifying risk of breast cancer and treatments thereof
DK1569961T3 (da) Splice variant af det menneskelige hypofysevæksthormon
AU2003294950A1 (en) Methods and kits for the selection of animals having certain mild production capabilities, based on the analysis of a polymorphism in the growth hormone receptor gene
Scherer Annotation and Functional Analysis of Human Chromosome 7 for Disease Research